Publication Name	World Journal of Hepatology
Manuscript ID	6767
Country	Greece

Received	2013-10-29 08:14
Peer-Review Started	2013-10-30 09:35
To Make the First Decision	2014-01-08 15:04
Return for Revision	2014-01-13 10:28
Revised	2014-02-10 18:25
Second Decision	2014-03-14 18:23
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-03-14 18:37
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-03-29 01:04
Typeset the Manuscript	2014-05-08 20:33
Publish the Manuscript Online	2014-05-20 15:05

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Update on inflammatory bowel disease in patients with primary sclerosing cholangitis
Manuscript Source	Invited Manuscript
All Author List	Christos Tsaitas, Anysia Semertzidou and Emmanouil Sinakos
Funding Agency and Grant Number
Corresponding Author	Emmanouil Sinakos, MD, 4th Internal Medicine Unit, University Hospital of Thessaloniki, 11A, Perdika Str, Pilea, 55535, Thessaloniki 54642, Greece. em_sinakos@yahoo.com
Key Words	Primary sclerosing cholangitis; Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease
Core Tip	Combination of primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) has recently arisen as a challenging research field. Recent data highlight the specific clinical and genetic traits that differentiate PSC-IBD from the two diseases individually. We reviewed the literature on colorectal neoplastic susceptibility in this subset of patients and the underlying pathogenetic mechanisms. We also emphasize the technological advances that have provided novel diagnostic tools for more accurate detection of dysplastic lesions. Finally, we present current guidelines on follow-up as well as all evidence available as to whether ursodeoxycholic acid should be used prophylactically against colorectal cancer.
Publish Date	2014-05-20 15:05
Citation	Tsaitas C, Semertzidou A, Sinakos E. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol 2014; 6(4): 178-187
URL	http://www.wjgnet.com/1948-5182/full/v6/i4/178.htm
DOI	http://dx.doi.org/10.4254/wjh.v6.i4.178

Full Article (PDF)	WJH-6-178.pdf
Full Article (Word)	WJH-6-178.doc
Manuscript File	6767-Review.docx
Answering Reviewers	6767-Answering reviewers.pdf
Copyright License Agreement	6767-Copyright assignment.pdf
Peer-review Report	6767-Peer review(s).pdf
Scientific Editor Work List	6767-Scientific editor work list.doc